SAN JOSE, Calif., June 19, 2013 /PRNewswire/ -- BD Biosciences, a segment of BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the launch of the BD LSRFortessa™ X-20 Cell Analyzer, the latest in its line of high-performance research flow cytometers.
The BD LSRFortessa X-20 Cell Analyzer delivers high-performance multicolor analysis with the most compact footprint in its class at just 30" x 29" (76.2 X 73.7 cm) and a height of 30" (76.2 cm). Recognizing that space is a valuable commodity in today's research environment, BD Biosciences designed the BD LSRFortessa X-20 Cell Analyzer to be compact without compromising the power needed.
Offering a new level of flexibility, the analyzer can be configured with up to five lasers to detect up to 20 parameters simultaneously. While popular laser choices include blue, red, violet, yellow-green and UV, a wide range of up to 34 available laser choices are available as excitation sources. Each excitation source is supported by new polygon detector arrays, and each polygon can support up to eight detectors for maximum flexibility in optical configuration.
The BD LSRFortessa X-20 Cell Analyzer is designed by BD's special order program that enables customers to configure BD flow cytometers and cell sorters to fit precise research and assay needs. This program is tailored to meet the needs of researchers at the leading edge of biomedical discovery. The platform is also supported by a full range of BD Biosciences reagents."The new BD LSRFortessa X-20 Cell Analyzer will enable researchers to conduct complex experiments with the additional parameters and increased sensitivity they need," said Alberto Mas, President, BD Biosciences. "Uncovering dim staining and rare cell populations is extremely valuable to complex multicolor assays, which are tools for advanced disease or drug development research." About BD BD is a leading global medical technology company that develops, manufactures and sells medical devices, instrument systems and reagents. The Company is dedicated to improving people's health throughout the world. BD is focused on improving drug delivery, enhancing the quality and speed of diagnosing infectious diseases and cancers, and advancing research, discovery and production of new drugs and vaccines. BD's capabilities are instrumental in combating many of the world's most pressing diseases. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, BD employs nearly 30,000 associates in more than 50 countries throughout the world. The Company serves healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public. For more information, please visit www.bd.com. Contact: Jamie YaccoPublic Relations(201) 847-4796 Jamie_Yacco@bd.com